News Related to Basal Cell Carcinoma

Related coverage linked through entity extraction aliases.

FDA Accepts sNDA for Aminolevulinic Acid Gel in Superficial Basal Cell Carcinoma

Mar 09, 2026

The FDA has accepted a supplemental new drug application for aminolevulinic acid hydrochloride plus red light therapy for superficial basal cell carcinoma, with a decision date set for September 28, 2026.

Adjuvant Pembrolizumab Maintains Survival Benefit Without Raising New Melanoma Risk in Stage II Disease

Mar 03, 2026

Secondary analysis of KEYNOTE-716 trial finds adjuvant pembrolizumab improves recurrence-free survival in stage IIB/IIC melanoma without increasing new primary melanoma risk, while reducing non-melanoma skin cancers.